Sarah E. Frew, PhD, MBA

Cell & Gene Therapy

& Business Development Advisor

Sarah has more than 20 years experience working to advance novel therapies in the healthcare industry as a researcher, developer and investor. As Managing Partner of Go Far Advisors, she provides advisory services to public and private life sciences companies, investors, and leading academic scientists to maximize the value of their breakthrough technologies and core competencies, with domain expertise in cell and gene therapies and genome editing. Previously, Sarah was Director of Corporate Contracts and Alliances at the Penn Center for Innovation at the University of Pennsylvania, where she drove strategic commercial partnerships for the University’s breakthrough technologies.  As Director of Business and Commercial Development at TetraLogic Pharmaceuticals, Sarah played an integral role in the company’s M&A and

Sarah Frew_photo.jpg

financing transactions, including the company’s 2013 IPO on Nasdaq. Dr. Frew has a PhD in cancer biology from the Massachusetts Institute of Technology, an MBA from the Wharton School of the University of Pennsylvania and a BS in Biological Sciences from Carnegie Mellon University. 

logo final_.png